RLMD analyst estimates
Relmada Therapeutics (RLMD) analyst ratings, the average price target and its range, and every firm's latest call.
RLMD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jun 18, 2026 | H.C. Wainwright | Relmada Therapeutics initiated with a Buy at H.C. Wainwright | $12.00 |
| Mar 13, 2026 | Mizuho Securities | Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' | $10.00 |
| Jan 23, 2026 | Leerink Partners | Relmada Therapeutics assumed at Outperform from Market Perform at Leerink | $8.00 |
| Dec 22, 2025 | Jefferies | Relmada Therapeutics initiated with a Buy at Jefferies | $9.00 |
| Jun 5, 2024 | Goldman Sachs | Goldman Sachs Downgrades Relmada Therapeutics Inc (RLMD) to Sell | $2.00 |
| Oct 13, 2022 | Oppenheimer | Relmada downgraded to Perform at Oppenheimer after MDD monotherapy trial miss | $7.00 |
| Oct 13, 2022 | Jefferies | Relmada Therapeutics downgraded to Hold from Buy at Jefferies | $8.00 |
- 6 firms rate RLMD: 6 buy, 0 hold, 0 sell.
- The average price target is $12.00 from 1 analysts, from $12.00 to $12.00.
Updated 2026-11-05 12:47 UTC